Healthcare / Drug Manufacturers - Specialty & GenericBSE
$79.50
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $745000.00 · quality 45.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$543M
P/E
3.1x
↓EV/EBITDA
N/A
•ROE
-18.2%
↓Gross Margin
17.1%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.3%
FCF CAGR
—
FCF margin
-0.7%
FCF / Net income
0.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $243.7M · net income $-15.9M · FCF $-1.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $243.7M | $243.7M | $305.9M | $274.9M | $172.2M |
| Net Income | $-15.9M | $-15.9M | $-5.2M | $-12.6M | $-15.5M |
| EBITDA | $-12.7M | $-12.7M | $-1.8M | $-10.4M | $-12.7M |
| EPS | -2.33 | -2.33 | -0.76 | -1.84 | -2.27 |
| Gross Margin | 17.1% | 17.1% | 17.0% | 15.6% | 16.5% |
| Operating Margin | -9.6% | -9.6% | -3.8% | -6.9% | -11.8% |
| Net Margin | -6.5% | -6.5% | -1.7% | -4.6% | -9.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.03 | 0.00 |
| Cash Flow | |||||
| Free Cash Flow | $-1.7M | $-1.7M | $745000.00 | $6.2M | $-1.8M |
| Returns | |||||
| ROE | -18.2% | -18.2% | -5.0% | -11.6% | -12.8% |
| Valuation | |||||
| P/E | 3.06 | 3.06 | — | — | — |
| P/B | 6.21 | 6.21 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -20.3% | -20.3% | 11.3% | 59.7% | — |
| EPS Growth | -206.6% | -206.6% | 58.7% | 18.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+162.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.76 → -2.33
Residual
+162.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.